Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revlimid in Cutaneous T-Cell Lymphoma
NCT00466921Phase 2Completed
- Sponsor
- Northwestern University
- Start
- Apr 2005
- Primary completion
- Apr 2010
- Countries
- 1
01
Overview
Phase 2, open-label trial of lenalidomide in mycosis fungoides (MF) and Sézary syndrome (SS), sponsored by Northwestern University. Primary endpoints: Overall Response Rate at 16 weeks and Progression-Free Survival at 6 years. Started Apr 2005; status: completed.
02
Drugs
lenalidomide
03
Conditions
mycosis fungoides (MF)Sézary syndrome (SS)
Beyond the preview
Go deeper on NCT00466921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00466921.